Coverage
Filings
Danish biosolutions company Novonesis on Thursday raised its full-year sales forecast after reporting strong growth for the first nine months of the year, citing a robust performance across its markets.
Novonesis on Wednesday laid out new long-term financial targets, aiming to accelerate sales growth and expand profit margins through 2030 as part of its new ‘GROW’ strategy.
Novonesis has successfully completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, the company announced.
| 29 Oct 2021 |
| Interim report for the first nine months of 2021 | 26 Oct 2021 |
| Novozymes announces its 2025 strategy: Unlocking growth – powered by biotech | 27 Sept 2021 |
| Transactions under Novozymes’ stock buyback program | 30 Aug 2021 |
| Transactions under Novozymes’ stock buyback program | 23 Aug 2021 |